Subgroup analyses from the SGLT-2 inhibitor trials in non-CKD populations suggest cardiac and kidney benefits are likely to be maintained in people co-prescribed an MRA with an SGLT-2 inhibitor, with no increased risk of hyperkalaemia caused by SGLT-2 inhibitor use [6, 14, 29–34]. Here, SLC5A2 is linked to chronic kidney disease.